CA2697529A1 - Receptor-targeting reagents - Google Patents

Receptor-targeting reagents Download PDF

Info

Publication number
CA2697529A1
CA2697529A1 CA2697529A CA2697529A CA2697529A1 CA 2697529 A1 CA2697529 A1 CA 2697529A1 CA 2697529 A CA2697529 A CA 2697529A CA 2697529 A CA2697529 A CA 2697529A CA 2697529 A1 CA2697529 A1 CA 2697529A1
Authority
CA
Canada
Prior art keywords
receptor
cancer
targeting reagent
targeting
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697529A
Other languages
English (en)
French (fr)
Inventor
Daniel A. Vallera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2697529A1 publication Critical patent/CA2697529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2697529A 2007-08-24 2008-08-25 Receptor-targeting reagents Abandoned CA2697529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95793607P 2007-08-24 2007-08-24
US60/957,936 2007-08-24
PCT/US2008/074268 WO2009029601A2 (en) 2007-08-24 2008-08-25 Receptor-targeting reagents

Publications (1)

Publication Number Publication Date
CA2697529A1 true CA2697529A1 (en) 2009-03-05

Family

ID=40388106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697529A Abandoned CA2697529A1 (en) 2007-08-24 2008-08-25 Receptor-targeting reagents

Country Status (5)

Country Link
US (2) US9155798B2 (enExample)
EP (1) EP2197909A4 (enExample)
JP (1) JP2010536386A (enExample)
CA (1) CA2697529A1 (enExample)
WO (1) WO2009029601A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
WO2011016031A2 (en) * 2009-08-03 2011-02-10 Yeda Research And Development Co. Ltd. Urinary biomarkers for cancer diagnosis
WO2012027494A1 (en) * 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
CN103865899B (zh) * 2012-12-17 2016-04-27 山西康宝生物制品股份有限公司 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用
EP3049526B1 (en) * 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
WO2016015015A1 (en) * 2014-07-24 2016-01-28 Baylor College Of Medicine Non-invasive radiofrequency field treatment for cancer therapy
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2020033398A1 (en) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating atii cell-dependent lung diseases
CN112912400B (zh) 2018-10-19 2025-05-30 明尼苏达大学董事会 Nk接合子分子及其使用方法
WO2020219599A1 (en) * 2019-04-23 2020-10-29 Aurora Oncology Compositions and methods for treatment of distentable tissues
WO2022135441A1 (zh) * 2020-12-22 2022-06-30 江苏恒瑞医药股份有限公司 抗il-4r抗体或其抗原结合片段的复合物及医药用途
US20240239857A1 (en) * 2021-05-19 2024-07-18 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Il-13ralpha2 targeted immunotoxins and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US142539A (en) * 1873-09-02 Improvement
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
DE19839671C2 (de) * 1998-09-01 2000-08-03 Forschungszentrum Juelich Gmbh Sensor zur Messung eines Magnetfeldes
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
WO2004096254A2 (en) 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Transferrin conjugates for tumor treatment

Also Published As

Publication number Publication date
WO2009029601A3 (en) 2010-04-22
EP2197909A4 (en) 2014-12-03
US20110091460A1 (en) 2011-04-21
EP2197909A2 (en) 2010-06-23
JP2010536386A (ja) 2010-12-02
US20160000868A1 (en) 2016-01-07
WO2009029601A2 (en) 2009-03-05
US9155798B2 (en) 2015-10-13

Similar Documents

Publication Publication Date Title
US9155798B2 (en) Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
Adams et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv
US10035853B2 (en) Site-specific antibody conjugation methods and compositions
AU2017200413B2 (en) Methods for identification of sites for IgG conjugation
Chen et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials
ES2534726T3 (es) Antígeno ED-A del fibrinógeno que está asociado con linfomas
AU2015218633A1 (en) Anti-DLL3 antibodies and drug conjugates for use in melanoma
AU2014312215A1 (en) Site-specific antibody conjugation methods and compositions
AU2015249887A1 (en) Novel anti-RNF43 antibodies and methods of use
WO2012027494A1 (en) Bispecific targeting reagents
CA2932476A1 (en) Novel anti-dpep3 antibodies and methods of use
JP2012507299A (ja) Ｌｉｇｈｔ標的分子およびその使用
CA3006738A1 (en) Novel anti-claudin antibodies and methods of use
US20180112004A1 (en) Engineered site-specific antibodies and methods of use
CA3005469A1 (en) Novel anti-emr2 antibodies and methods of use
WO2025209500A1 (zh) Nectin-4单域抗体及其用途
AU2016378744A1 (en) Novel anti-UPK1B antibodies and methods of use
WO2025118472A1 (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
Boskovitz et al. Human/murine chimeric 81C6 F (ab′) 2 fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma
JP2025522306A (ja) Ｈｅｒ２－結合剤およびその使用
CN116925220A (zh) Il20rb中和抗体及其医药用途
WO2026097082A1 (en) Tcr mimetic t cell engaging antibodies targeting human leukocyte antigen cathepsin g peptide complex and cd3 and related methods
KR20260045855A (ko) 항-Trop2 항체, 상기 항체를 포함하는 접합체 및 이의 응용
NZ631476A (en) Antigens associated with inflammatory bowel disease
NZ631476B2 (en) Antigens associated with inflammatory bowel disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130517

FZDE Discontinued

Effective date: 20160512